Day: November 10, 2021

XEN1101 X-TOLE Presentations Scheduled at AES 2021 with Planning Underway for Phase 3 Initiation in 2022 Conference Call at 4:30 pm ET Today BURNABY, British Columbia, Nov. 10, 2021 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update. Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer stated, “We were incredibly excited last month to announce positive topline results from our Phase 2b X-TOLE clinical trial, which demonstrated impressive efficacy for XEN1101 in ‘difficult-to-treat’ adult patients with focal epilepsy. With its differentiated potassium channel mechanism of action, strong efficacy data, and ‘ease-of-use’ attributes, including once-a-day...

– SKYTROFA® (lonapegsomatropin-tcgd) approved by the FDA in the U.S. as a once-weekly treatment for pediatric growth hormone deficiency (GHD); commercially launched in October 2021. – Completed enrollment in Phase 3 PaTHway Trial of TransCon™ PTH. Topline results expected Q1 2022 and 84-week topline results from Phase 2 PaTH Forward Trial expected later this quarter. – Company to hold a virtual R&D update on TransCon PTH, TransCon CNP, and TransCon TLR7/8 Agonist in mid-December to review continued pipeline progress. – Strengthened balance sheet with a successful public offering of American Depositary Shares raising net proceeds of approximately $436 million. COPENHAGEN, Denmark, Nov. 10, 2021 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND), today announced financial results for the third quarter ended September 30,...

Company delivered higher than expected net sales of approximately $543,000 on 1.5 million pounds of tomatoes sold in Q3 2021, as second growing season at company’s Morehead, Ky. high-tech indoor farm ramps up in Q4 2021 High-tech indoor farms currently under construction in Kentucky: 60-acre tomato, 15-acre leafy green and 30-acre berry facilities expected to be operational by end of 2022 and 10-acre Morehead leafy green facility in 2023 MOREHEAD, Ky., Nov. 10, 2021 (GLOBE NEWSWIRE) — AppHarvest, Inc. (NASDAQ: APPH, APPHW), a leading AgTech company, public benefit corporation and Certified B Corp building some of the world’s largest high-tech indoor farms to grow affordable, nutritious fruits and vegetables at scale while providing good jobs in Appalachia, announced today its operating and financial results for the quarter ending...

VANCOUVER, British Columbia, Nov. 10, 2021 (GLOBE NEWSWIRE) — Tree Island Steel (”Tree Island” or the ”Company”) (TSX: TSL) announced today its financial results for the three month and nine months ended September 30, 2021. For the three-month period ended September 30, 2021, revenues increased by $31.4 million to $84.6 million, from pricing increases and higher demand, particularly in the Construction and Industrial market segments. Gross profit for the third quarter increased to $21.8 million, from $6.7 million in the same period in 2020, from increased sales volumes in the period and cost management. EBITDA amounted to $20.0 million, compared to $4.3 million during the same period in 2020. For the nine months ended September 30, 2021, revenues increased by $64.2 million to $225.9 million when compared...

– Phase 1/2 study of CFT7455, a Novel IKZF1/3 Degrader, Progressing with Data Expected in 2022; Trial-in-Progress Poster Accepted for Presentation at 63rd ASH Annual Meeting – – Investigational New Drug (IND) Application for CFT8634, a Degrader Targeting BRD9 for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors, On Track for Submission by YE 2021 – – Development Candidate CFT1946, a BRAF V600X Degrader, in IND-enabling Activities; C4T to Advance CFT1946 Independently – – On Track to Deliver Four Clinical-stage Programs by YE 2022 – WATERTOWN, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today reported business highlights...

$9.4 million in total revenue, up 5% year-over-yearExcluding Sample Transport, total revenue was $9.3 million, up 26% year-over-yearStrong cash position of $98.0 million supports investment in long-term growth strategy HOLLISTER, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) — Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading provider of critical reagents for the development and production of biopharmaceutical products, including drug therapies, novel vaccines, and molecular diagnostics, today announced financial results for the third quarter ended September 30, 2021. “Teknova performed very well during the third quarter of 2021. We met robust customer demand for our Lab Essentials and Clinical Solutions products and made meaningful progress in advancing our strategic priorities, including investing in our manufacturing capacity...

DAVIS, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) — Marrone Bio Innovations, Inc. (NASDAQ: MBII), an international leader in sustainable bioprotection and plant health solutions, has provided its financial results for the third quarter ended September 30, 2021. Key results include:Strategic focus on global expansion in the major row crops was a key contributor to the 12% revenue growth for the third quarter. Sales of biological fungicides also increased during the period. Stronger mix of higher margin seed treatments led to gross profit of 61.4% in the third quarter, the 12th consecutive quarter of gross margins in excess of 50%. The net loss in the third quarter of 2021 was $4.9 million, as compared with a net loss of $6.1 million in the third quarter of 2020. Higher revenues and gross margin expansion, coupled with continued cost...

Positive results reported from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis provided proof-of-concept for ATYR1923 and validation for tRNA synthetase biology platform and NRP2 target. Registrational trial for ATYR1923 in pulmonary sarcoidosis expected to initiate in 2022. September follow-on common stock offering generated $80 million in net proceeds. Company to host conference call and webcast today, November 10th, at 5:00 p.m. EST / 2:00 p.m. PST. SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced third quarter 2021 results and provided a corporate update. “The third quarter was a major inflection point for aTyr; we demonstrated, via clinical...

Revenue of $147.9 Million, an increase of 12% year-over-year GLENDALE, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) — LegalZoom.com, Inc. (NASDAQ: LZ), today announced results for its third quarter ended September 30, 2021, including the following highlights:Revenue was $147.9 million, up 12% year-over-year.Transaction revenue was $66.9 million, up 5% year-over-year driven by business formations of 106,000, down 9% year-over-year and a 16% improvement in average order value. Subscription revenue was $73.3 million, up 24% year-over-year. We had 1,264,000  subscription units as of September 30, 2021, with 49,000 net units added in the quarter. Partner revenue was $7.7 million, down 8% year-over-year.Gross margin was 68% for the quarter, up from 67% in the third quarter of 2020 as the revenue mix shifted toward subscription revenue. Net...

CALGARY, Alberta, Nov. 10, 2021 (GLOBE NEWSWIRE) — Birchcliff Energy Ltd. (“Birchcliff” or the “Corporation”) (TSX: BIR) is pleased to announce its financial and operational results for the three and nine months ended September 30, 2021, its updated 2021 guidance and its preliminary outlook for 2022. “Birchcliff delivered exceptional third quarter results, highlighted by record quarterly adjusted funds flow(1) of $168.1 million and free funds flow(1) of $150.1 million, with quarterly average production of 84,924 boe/d,” commented Jeff Tonken, President and Chief Executive Officer of Birchcliff. “As a result of this excellent performance, we are swiftly reducing our debt.” “For the remainder of 2021, we will continue to focus on maintaining our low-cost structure, free funds flow generation and strengthening our already strong balance...